title: Two-year outcomes of the sirolimus-eluting stent according to unprotected left main lesion.
abstract: BACKGROUND
  The data of long-term outcomes of sirolimus-eluting stent (SES) according to lesion location of unprotected left main coronary artery (LMCA) is scarce.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the long-term outcomes after implantation of the SES in LMCA.
  
  
  METHODS
  A total of 84 patients (51 males) who had undergone SES implantation for the treatment of native LMCA stenosis were enrolled. The patients were divided into 2 groups based on angiographic lesion location: those with significant stenosis in the ostium and/or body (group 1; n = 39) and those involving bifurcation (group 2; n = 45).
  
  
  RESULTS
  All of the group 1 patients were treated with simple lesion coverage while different stenting techniques were used in group 2 (cross-over: 44.8%, T: 6.7%, kissing: 37.8%, and crush techniques: 11.1%). The 8-month quantitative angiographic findings and in-hospital and 2 year rates of major adverse cardiac events (MACE) were compared between the 2 groups. Although angiographic success and in-hospital MACE rates were similar in both groups with 1 cardiac death due to acute stent thrombosis in group 2, at 2-year follow-up, the MACE rate was significantly higher in group 2 than in group 1 at 2 years (22.2% vs 2.6%, respectively, P = 0.008). Coronary angiography revealed a significantly higher binary restenosis rate in group 2 compared with group 1 (20% vs 0%, respectively, P = 0.003).
  
  
  CONCLUSIONS
  Interventional treatment using SES in left main lesions showed favorable short-term and long-term outcomes in selected patients with lesion location being an important determinant of clinical and angiographic outcomes.
authors: Cardiology Division, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea.
authors: Ung
authors: U
authors: Kim
authors: Jong-Seon
authors: JS
authors: Park
authors: Sang-Hoon
authors: SH
authors: Seol
authors: Tae-Hyun
authors: TH
authors: Yang
authors: Sung-Man
authors: SM
authors: Kim
authors: Dae-Kyung
authors: DK
authors: Kim
authors: Doo-Il
authors: DI
authors: Kim
authors: Dong-Soo
authors: DS
authors: Kim
authors: Won-Jae
authors: WJ
authors: Lee
authors: Sang-Hee
authors: SH
authors: Lee
authors: Geu-Ru
authors: GR
authors: Hong
authors: Dong-Gu
authors: DG
authors: Shin
authors: Young-Jo
authors: YJ
authors: Kim
authors: Bong-Sup
authors: BS
authors: Shim
authors: Yoon-Kyung
authors: YK
authors: Cho
authors: Hyung-Seop
authors: HS
authors: Kim
authors: Chang-Wook
authors: CW
authors: Nam
authors: Seung-Ho
authors: SH
authors: Hur
authors: Kwon-Bae
authors: KB
authors: Kim
authors: Yoon-Nyun
authors: YN
authors: Kim
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000000981:diagnostic imaging / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D020123:Sirolimus / Q000008:administration & dosage*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020123:Sirolimus